Older patients, females, and those with comorbidities were more likely to be on multiple medications.
Drugs in the Pipeline
Portola Pharmaceuticals, Bristol-Myers Squibb Company, and Pfizer announced results from the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors - Apixaban) study with andexanet alfa as a reversal agent for Eliquis (apixaban).
This is an investigational use for Eliquis.
For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is beneficial and appropriate for those with one dose-reduction criterion, according to a study published online in JAMA Cardiology.
If Tybost is given with atazanavir or darunavir, coadministration with rivaroxaban is not recommended due to a potentially increased bleeding risk.
Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.
Findings from a study published in the British Journal of Clinical Pharmacology showed that apixaban appeared to be an appropriate alternative to warfarin for patients with severe renal impairment.
AHA 2017 Scientific Sessions
Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure.
The Food and Drug Administration (FDA) has approved the first generics of Eliquis (apixaban; Bristol-Myers Squibb and Pfizer) tablets. Apixaban, a factor Xa inhibitor, is indicated: To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism…
Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA's Accelerated Approval pathway.